List of Excipients in Branded Drug LOSARTAN POTASSIUM

Generic Drugs Containing LOSARTAN POTASSIUM

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	losartan potassium	0054-0123	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	losartan potassium	0054-0123	D&C YELLOW NO. 10
Hikma Pharmaceuticals USA Inc	losartan potassium	0054-0123	FD&C BLUE NO. 2
Hikma Pharmaceuticals USA Inc	losartan potassium	0054-0123	HYPROMELLOSE
Hikma Pharmaceuticals USA Inc	losartan potassium	0054-0123	LACTOSE MONOHYDRATE
Hikma Pharmaceuticals USA Inc	losartan potassium	0054-0123	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	losartan potassium	0054-0123	POLYETHYLENE GLYCOL

What are the Most Frequently-Used Excipients in LOSARTAN POTASSIUM?

# Of NDCs	Excipient
1	ACID YELLOW 3
7	ALUMINUM OXIDE
37	ANHYDROUS LACTOSE
50	CARNAUBA WAX
273	CELLULOSE, MICROCRYSTALLINE
5	CI 77891
5	COLLOIDAL SILICON DIOXIDE

Losartan Potassium Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Losartan potassium is a mature, off-patent angiotensin II receptor blocker with extensive generic competition. The strongest commercial opportunities are not basic immediate-release tablets. They are differentiated dosage forms, pediatric liquids, orally disintegrating tablets, fixed-dose combinations, adherence-focused packaging, and excipient platforms that improve manufacturability, tolerability, or access for patients with dietary restrictions.

What is the regulatory and commercial status of losartan potassium?

Losartan potassium is approved for hypertension, reduction of stroke risk in certain patients with hypertension and left ventricular hypertrophy, and diabetic nephropathy in patients with type 2 diabetes and hypertension. The reference product is Cozaar, marketed by Merck. The drug is also sold in combination with hydrochlorothiazide as Hyzaar and generic equivalents.

Attribute	Losartan potassium
Drug class	Angiotensin II receptor blocker
Reference product	Cozaar
Common strengths	25 mg, 50 mg, 100 mg
Common dosage form	Immediate-release film-coated tablet
Combination product	Losartan potassium/hydrochlorothiazide
Primary FDA route	Abbreviated New Drug Application for generic tablets
Biosimilar pathway	Not applicable
Patent position	Core composition and original product protection expired
Main commercial constraint	High generic competition and low unit pricing
Main opportunity	Differentiated delivery, pediatric use, adherence, and combination products

Losartan is administered once daily in most patients, although some patients require dose adjustment or twice-daily administration. The tablet market is highly commoditized. Product selection is often driven by reimbursement, pharmacy inventory, supply reliability, tablet appearance, bottle size, and manufacturer continuity rather than by active-ingredient differentiation.

When did losartan potassium lose exclusivity?

The core U.S. patent estate for losartan was filed in the late 1980s and early 1990s. Merck's principal losartan patent, U.S. Patent No. 5,138,069, covered substituted imidazole compounds, including losartan. Its effective patent term expired around 2010, subject to applicable patent-term adjustments and pediatric exclusivity. Generic losartan products entered the U.S. market beginning in 2010 after settlement and regulatory developments involving multiple ANDA applicants.

Exclusivity element	Commercial effect
Core losartan compound patent	Expired
Cozaar product exclusivity	Expired
Losartan/hydrochlorothiazide combination protection	Expired
Current generic entry barrier	No meaningful core patent barrier
Pediatric exclusivity	Historical, no longer commercially blocking
Biosimilar exclusivity	Not applicable

The current market is therefore controlled by generic economics, manufacturing reliability, regulatory compliance, and channel access. A new company cannot rely on the active ingredient alone to support premium pricing.

What patents protect losartan potassium today?

Core patent protection for losartan potassium has expired in the United States and major European markets. Original patents covering the losartan chemical class and early formulations no longer provide a practical barrier to ordinary generic tablets.

Are there Paragraph IV challenges for losartan?

Paragraph IV litigation was commercially relevant when generic applicants challenged the remaining Cozaar and Hyzaar patents. That period has passed for the core product. New ANDA applicants generally face ordinary product-specific Orange Book review rather than a meaningful originator patent blockade.

Any applicant pursuing a new losartan formulation should conduct a separate, current Orange Book and global patent search. Formulation, manufacturing, polymorph, packaging, or combination patents can create narrower risks even when the basic compound patent has expired. A formulation patent must still satisfy novelty, non-obviousness, written description, enablement, and patent-term requirements.

What is the Orange Book status of losartan?

FDA-approved losartan tablets and losartan/hydrochlorothiazide tablets are listed in the Orange Book by reference product and approved generic product. The Orange Book is the controlling source for current listed patents, therapeutic-equivalence ratings, and exclusivity information. Losartan immediate-release tablets are generally marketed through ANDAs with therapeutic-equivalence ratings, subject to the product-specific FDA listing. [1]

What excipients are used in losartan potassium tablets?

Reference and generic losartan tablets typically use conventional direct-compression or wet-granulation excipients. Labeling for Cozaar identifies excipients such as microcrystalline cellulose, lactose monohydrate, pregelatinized starch, magnesium stearate, hypromellose, hydroxypropyl cellulose, titanium dioxide, and carnauba wax, depending on the dosage form and coating system. [2]

Core excipient functions

Excipient category	Typical options	Development purpose
Diluent	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Tablet mass and compression
Binder	Pregelatinized starch, povidone, hydroxypropyl cellulose	Granule strength and tablet integrity
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Rapid tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and tooling control
Glidant	Colloidal silicon dioxide	Powder flow
Film former	Hypromellose, polyvinyl alcohol	Coating and appearance
Plasticizer	Polyethylene glycol, propylene glycol	Film flexibility
Opacifier or colorant	Titanium dioxide, iron oxides	Light protection and product identification

Losartan formulation development should focus on powder flow, content uniformity, disintegration, dissolution, moisture sensitivity, and tablet robustness. The active ingredient is used at a relatively high dose compared with many highly potent cardiovascular drugs, so excipient selection materially affects tablet size.

Which excipient strategy is strongest for a generic losartan tablet?

The most defensible standard strategy is a low-cost, robust formulation based on microcrystalline cellulose, a rapid disintegrant, a low level of lubricant, and a conventional film coat. The design should minimize unnecessary excipient complexity.

Strategy 1: Lactose-containing immediate-release tablet

A lactose/MCC system can provide low cost, good compressibility, and broad supplier availability. It is commercially appropriate for mass-market products where lactose intolerance concerns are limited and the target is a conventional AB-rated tablet.

Risks include incompatibility concerns for patients avoiding lactose, supplier variability, and potential sensitivity to moisture or processing conditions.

Strategy 2: Lactose-free tablet

A lactose-free platform using microcrystalline cellulose, mannitol, starch, or dibasic calcium phosphate can support differentiated labeling and institutional procurement. The commercial benefit is greater when the product is also low in colorants, gluten-free where supportable, and packaged for chronic-use adherence.

A lactose-free claim must be supported by raw-material specifications, supplier controls, cross-contamination controls, and finished-product testing.

Strategy 3: Sodium-conscious formulation

Losartan potassium contains potassium as the counterion, but the formulation can avoid sodium-containing excipients such as sodium starch glycolate or croscarmellose sodium if the target population or label strategy favors sodium minimization. This distinction should not be presented as a low-potassium product. The active ingredient itself is a potassium salt.

Possible alternatives include crospovidone as disintegrant and sodium-free glidant and coating systems. The commercial value is niche rather than broad, because the potassium contribution from the active ingredient and the clinical context remain relevant.

Strategy 4: High-throughput direct compression

Direct compression can lower manufacturing cost and reduce process steps. A formulation using spray-dried lactose or co-processed MCC, a high-efficiency disintegrant, colloidal silicon dioxide, and magnesium stearate may support continuous or high-speed batch production.

The development target should be a narrow compression-force operating window, low weight variation, acceptable friability, and rapid dissolution across the 25 mg, 50 mg, and 100 mg strengths.

What formulations are protected by commercial differentiation?

Losartan's commercial white space is concentrated in dosage forms that address administration barriers.

Orally disintegrating tablets

An orally disintegrating tablet could target older adults, patients with dysphagia, and patients who lack immediate access to water. Mannitol, crospovidone, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and taste-masking agents are common development tools.

The main technical risks are the bitter or medicinal taste of the active, moisture sensitivity, friability, and packaging cost. Unit-dose alu-alu blister packaging may be necessary.

A successful ODT can support a 505(b)(2) strategy if the product introduces a clinically meaningful change or relies on relevant bridging data. If it is merely an equivalent oral dosage form, an ANDA pathway may be more appropriate, depending on the reference listed drug and FDA requirements.

Pediatric oral liquid

A ready-to-use or powder-for-reconstitution suspension could address pediatric hypertension and patients unable to swallow tablets. Potential excipient systems include glycerin, sorbitol, propylene glycol or polyethylene glycol where justified, hypromellose, xanthan gum, microcrystalline cellulose/carboxymethylcellulose systems, citrate or phosphate buffers, sweeteners, and flavoring agents.

The formulation must control:

• Dose uniformity after shaking
• Sedimentation and redispersibility
• Chemical stability
• Microbial preservation
• Palatability
• Measuring-device accuracy
• Sugar and alcohol content
• Container compatibility

A preservative-free, sugar-free, alcohol-free liquid would have a clearer institutional and pediatric positioning than a basic flavored suspension. FDA pediatric labeling and excipient exposure should guide development. [3]

Sprinkle or dispersible granules

Granules that can be mixed with soft food or dispersed in water may be attractive for geriatric, pediatric, and enteral-feeding use. The product must demonstrate stability after dispersion, dose recovery, and compatibility with feeding tubes if that use is claimed.

Fixed-dose combinations

Losartan/hydrochlorothiazide is already established, so the opportunity is operational rather than foundational. Potential differentiation includes:

• Smaller tablets
• Lower-dose titration packs
• Lactose-free or colorant-reduced products
• Blister packaging
• Pediatric or geriatric administration formats
• Improved supply reliability

Other combinations involving amlodipine or other antihypertensives would face clinical, regulatory, and patent analyses separate from losartan's expired core protection.

How strong is the patent estate for a new losartan excipient platform?

The patent estate is weak for conventional losartan tablets and potentially stronger for genuinely differentiated delivery systems.

Innovation	Patent potential	Commercial value
New tablet excipient blend with routine substitutions	Low	Low to moderate
Lactose-free conventional tablet	Low	Moderate procurement value
Taste-masked ODT with defined performance	Moderate	Moderate to high
Stable pediatric suspension	Moderate	High if clinically useful
Novel multiparticulate or modified-release system	Moderate to high	Uncertain because once-daily immediate release is established
New fixed-dose combination	Moderate	Depends on clinical and market positioning
Manufacturing process with measurable yield or impurity advantage	Moderate	High for cost leadership
Packaging system improving stability or adherence	Low to moderate	Moderate

Routine excipient substitution usually has limited patent strength. Stronger protection requires a defined composition, a reproducible manufacturing process, and unexpected performance, such as improved dissolution under discriminatory conditions, improved stability, reduced impurity formation, or superior dose uniformity.

What manufacturing and IP barriers affect losartan products?

The key manufacturing barriers are not raw-material scarcity alone. They include control of polymorphic form, particle-size distribution, blend segregation, lubrication, dissolution, and impurity formation.

A competitive formulation should establish:

1. Active-ingredient particle-size specifications.
2. Excipient supplier qualification and dual sourcing.
3. Blend uniformity controls.
4. Dissolution profiles across all strengths.
5. Stability under ICH long-term and accelerated conditions.
6. Packaging protection against moisture and light.
7. Control of nitrosamines and other potentially mutagenic impurities where relevant to the supply chain.
8. Process validation for commercial-scale compression and coating.

Manufacturing patents may be more valuable than composition patents when they reduce solvent use, improve yield, shorten cycle time, or reduce impurity burden. Any process patent must be evaluated against expired prior art and freedom-to-operate risks in each target jurisdiction.

Which companies are challenging or competing with losartan products?

The market has included major generic manufacturers such as Teva, Sandoz, Mylan, Lupin, Torrent, Zydus, Dr. Reddy's, and other regional suppliers. Competition is fragmented, and product availability can change with FDA approvals, manufacturing transfers, recalls, and wholesaler purchasing.

The strongest competitive advantages are:

• Reliable API sourcing
• Consistent FDA compliance
• Multiple strengths from one platform
• Low-cost direct compression
• Retail and institutional distribution
• Combination-product capability
• Differentiated pediatric or dysphagia-friendly formats

Biosimilar competition is irrelevant because losartan is a chemically synthesized small molecule. Generic competition is the principal market force.

What generic launch risks exist for losartan potassium?

A conventional generic launch faces low patent risk but high commercial risk.

Risk	Impact
Price erosion	High
Therapeutic-equivalence competition	High
API supply disruption	Moderate to high
FDA manufacturing observations	High
Recall or impurity event	High
Retail substitution	High
Differentiated dosage-form adoption	Moderate
International regulatory divergence	Moderate

A new entrant should avoid a single-SKU strategy. A 25 mg, 50 mg, and 100 mg platform, paired with a commercially meaningful excipient or packaging differentiator, is more defensible than a single conventional tablet.

How does losartan compare with other ARBs?

Drug	Generic maturity	Formulation opportunity	Commercial implication
Losartan	Highly mature	Pediatric liquid, ODT, combinations	High volume, low price
Valsartan	Highly mature	Combination and liquid formats	Strong cardiovascular competition
Irbesartan	Mature	Conventional tablets and combinations	More limited differentiation
Candesartan cilexetil	Mature	Solubility and formulation work	Potentially greater technical complexity
Olmesartan medoxomil	Mature	Combination and adherence products	Established generic competition
Telmisartan	Mature	Solubility and combination platforms	Differentiation may rely on formulation

Losartan's advantage is broad clinical familiarity, multiple approved strengths, and a large installed patient base. Its disadvantage is severe price competition and limited opportunity for a premium conventional tablet.

What licensing deals could create value?

The most practical licensing opportunities involve:

• Pediatric suspension technology
• Taste-masking systems
• ODT manufacturing platforms
• Co-processed excipients
• Continuous direct-compression technology
• Low-moisture film-coating systems
• Unit-dose adherence packaging
• Regional distribution rights
• Combination-product development

An excipient company can license a platform to multiple generic manufacturers, but it should avoid broad claims that read on routine substitution. A formulation license is more valuable when it includes validated manufacturing parameters, stability data, regulatory documentation, and supplier qualification packages.

Key Takeaways

• Losartan potassium's core U.S. patent and exclusivity protections have expired.
• The immediate-release tablet market is generic, price-sensitive, and difficult to differentiate.
• A conventional lactose/MCC tablet remains the lowest-cost development route.
• Higher-value opportunities include lactose-free tablets, ODTs, pediatric liquids, sprinkle products, and adherence packaging.
• A potassium-salt active cannot be positioned as a low-potassium product merely by removing sodium-containing excipients.
• Patent strength is limited for routine excipient substitutions and stronger for defined, performance-driven delivery systems.
• Manufacturing reliability, API quality, dissolution control, and regulatory execution are more important than core compound IP.
• Biosimilar risk does not apply; generic substitution is the relevant competitive threat.
• The most credible commercial strategy is a multi-strength product platform combined with one differentiated dosage form and a cost-efficient manufacturing process.

FAQs

Can losartan potassium be formulated without lactose?

Yes. Microcrystalline cellulose, mannitol, starch, and other non-lactose diluents can replace lactose. The product requires separate control of tablet hardness, disintegration, dissolution, and stability.

Is losartan potassium suitable for an orally disintegrating tablet?

Yes, but taste masking, friability, moisture protection, and rapid disintegration are central development issues. Unit-dose blister packaging may be required.

Can a pediatric losartan liquid support a new patent?

Potentially. Patentability depends on the specific composition, manufacturing process, stability profile, and demonstrated technical effect. A routine syrup or suspension is less likely to provide strong protection.

Does losartan potassium have biosimilar competition?

No. Losartan is a small-molecule drug regulated through generic pathways, principally ANDAs in the United States.

Is losartan/hydrochlorothiazide a separate patent opportunity?

The original combination protection has expired. A new opportunity would require a differentiated dosage form, clinically relevant dosing benefit, manufacturing improvement, or another patentable technical feature.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
2. Merck Sharp & Dohme LLC. (2023). Cozaar (losartan potassium) tablets prescribing information. U.S. Food and Drug Administration.
3. U.S. Food and Drug Administration. (2016). Safety of excipients used in pediatric medicines. FDA.
4. U.S. Food and Drug Administration. (2019). ANDAs for certain highly soluble, highly permeable drugs. FDA.
5. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.
6. U.S. Patent No. 5,138,069. (1992). Imidazole derivatives. U.S. Patent and Trademark Office.